Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Table 2

Number of CL lesions in different sites between two treatment groups.

Lesion site	ZS (10 mg/kg/day)	MA (20 mg/kg/day)
Head and neck	19 (44.3%)	56 (44.1%)
Upper limb	18 (44.9%)	56 (44.1%)
Lower limb	5 (11.6%)	14 (11%)
Trunk	1 (2.3%)	1 (0.8%)

Frequency percentages in CL studied patients (%).